Vaginal Misoprostol for Cervical Priming before Gynaecological Procedures on Non
Abstract
Background
Misoprostol has been extensively researched for its use in obstetrics and has proved to be a very effective cervical softening
agent before termination of pregnancy. The beneficial effects on cervical ripening may make misoprostol a desirable agent for
helping cervical dilatation on non pregnant women also. The objective is to study the efficacy of preoperative vaginal application
of misoprostol as cervical priming agent before gynaecological procedures on non pregnant women.
Methods
Design: A randomized controlled trial.
Setting: Department of Gynaecology and Obstetrics of two medical colleges.
Participants: 468 non pregnant pre-menopausal nulli-parous or parous women scheduled to have diagnostic D&C or diagnostic
hysteroscopy operations.
Interventions: 400 mcg intravaginal misoprostol (229 women) in the study group and 400 mg intravaginal metronidazole as
placebo (231women) in control group.
Outcome Measure: The main outcome measures were baseline cervical width at the beginning of the procedures, the number of
women who required further cervical dilatation, time taken for dilatation, side effects and other complications.
Results : Base line cervical width in the study group was significantly higher than control group (4.6±0.8 mm vs. 3.8±0.7 mm, p
< 0.0001). 141 (61.57%) cases required further cervical dilatation in the study group compared to 206 (89.18%) in the control
group (p < 0.0001). Time taken for further cervical dilatation was significantly lower in the study group compared to control group
(48.3±18.4 sec vs. 68.6±17.3 sec, p < 0.0001). Cervical injury and uterine perforation occurred in 12 and 3 women respectively
in the control group compared to 1 and 0 women respectively in the misoprostol group. Two most common side effects of
vaginal misoprostol were mild lower abdominal pain (21%) and slight vaginal bleeding (09.2%) which were within tolerable limit.
Conclusion: Preoperative vaginal application of misoprostol before gynaecological procedures on non pregnant women
decreases the cervical resistance, facilitates the cervical dilatation and operative procedures minimizing cervical or uterine
injuries.
Misoprostol has been extensively researched for its use in obstetrics and has proved to be a very effective cervical softening
agent before termination of pregnancy. The beneficial effects on cervical ripening may make misoprostol a desirable agent for
helping cervical dilatation on non pregnant women also. The objective is to study the efficacy of preoperative vaginal application
of misoprostol as cervical priming agent before gynaecological procedures on non pregnant women.
Methods
Design: A randomized controlled trial.
Setting: Department of Gynaecology and Obstetrics of two medical colleges.
Participants: 468 non pregnant pre-menopausal nulli-parous or parous women scheduled to have diagnostic D&C or diagnostic
hysteroscopy operations.
Interventions: 400 mcg intravaginal misoprostol (229 women) in the study group and 400 mg intravaginal metronidazole as
placebo (231women) in control group.
Outcome Measure: The main outcome measures were baseline cervical width at the beginning of the procedures, the number of
women who required further cervical dilatation, time taken for dilatation, side effects and other complications.
Results : Base line cervical width in the study group was significantly higher than control group (4.6±0.8 mm vs. 3.8±0.7 mm, p
< 0.0001). 141 (61.57%) cases required further cervical dilatation in the study group compared to 206 (89.18%) in the control
group (p < 0.0001). Time taken for further cervical dilatation was significantly lower in the study group compared to control group
(48.3±18.4 sec vs. 68.6±17.3 sec, p < 0.0001). Cervical injury and uterine perforation occurred in 12 and 3 women respectively
in the control group compared to 1 and 0 women respectively in the misoprostol group. Two most common side effects of
vaginal misoprostol were mild lower abdominal pain (21%) and slight vaginal bleeding (09.2%) which were within tolerable limit.
Conclusion: Preoperative vaginal application of misoprostol before gynaecological procedures on non pregnant women
decreases the cervical resistance, facilitates the cervical dilatation and operative procedures minimizing cervical or uterine
injuries.
Saha, S. P., Bhattacharjee, N., & Baru, G. (2007). Vaginal Misoprostol for Cervical Priming before Gynaecological Procedures on Non. International Journal of Health Sciences, 1(2). Retrieved from https://ijhs.qu.edu.sa/index.php/journal/article/view/82
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
Copyright and license info is not available